Sichuan Kelun-Biotech Biopharmaceutical Syas New Drug Clearance For Adc Drug Skb518
April 21 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical 6990.HK:
INVESTIGATIONAL NEW DRUG CLEARANCE FOR INNOVATIVE ADC DRUG SKB518 BY US FDA
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Palantir Q1 2026 Earnings Preview — Is PLTR a Buy at $144?

ORCL Stock: Why Oracle May Be the Beaten-Down Tech Giant Ready for a Comeback

Nvidia Makes First Bet on Legal AI, Invests $50 Million in Legora

POET Technologies Stock Could Still Surge in 2026, but the Bar for a Breakout Is Higher Now

Is Lululemon Stock a Buy or a Risky Bet Amidst Financial Pressure and Management Changes?

Tradingkey






